Susquehanna International Group, LLP Pds Biotechnology Corp Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.93 - $4.23 $58,893 - $85,023	20,100 Added 120.36%	36,800 $140,000
Q2 2024 Aug 15, 2024	SELL	$2.55 - $4.02 $334,305 - $527,022	-131,100 Reduced 88.7%	16,700 $48,000
Q1 2024 May 07, 2024	SELL	$3.85 - $6.59 $148,610 - $254,374	-38,600 Reduced 20.71%	147,800 $585,000
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $108,230 - $180,292	27,400 Added 17.23%	186,400 $926,000
Q3 2023 Nov 14, 2023	BUY	$4.8 - $6.4 $118,080 - $157,440	24,600 Added 18.3%	159,000 $802,000
Q2 2023 Aug 11, 2023	BUY	$5.03 - $9.9 $422,017 - $830,610	83,900 Added 166.14%	134,400 $676,000
Q1 2023 May 16, 2023	SELL	$5.68 - $11.99 $399,304 - $842,897	-70,300 Reduced 58.2%	50,500 $310,000
Q4 2022 Feb 14, 2023	BUY	$3.28 - $13.2 $190,568 - $766,920	58,100 Added 92.66%	120,800 $1.59 Million
Q3 2022 Nov 14, 2022	SELL	$2.97 - $5.79 $175,230 - $341,610	-59,000 Reduced 48.48%	62,700 $186,000

4.32M

253K

70.4K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $57.5M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.